Navigation Links
Perceptive Informatics Appoints Medical Imaging Scientific Advisors
Date:12/4/2007

BOSTON, Dec. 4 /PRNewswire-FirstCall/ -- Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), has selected experts in the fields cardiovascular, musculoskeletal, oncology, and central nervous system imaging to serve as scientific advisors. These advisors are working with the Perceptive Informatics Medical Imaging functional units to help guide clients in making key decisions regarding the imaging related aspects of clinical programs from early stage development through post- marketing studies.

"Scientific advances across a broad range of therapeutic areas are increasing the potential for medical imaging to serve as an endpoint in determining the safety and efficacy of new treatments in clinical trials," said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics at PAREXEL International. "By combining the regulatory and drug development experience of our global medical imaging team with the specialized therapeutic area expertise of these advisors, we are helping clients to make better and more informed decisions regarding the best use of medical imaging in their development programs."

"Our scientific advisors represent a valuable resource to clients who look to Perceptive for the medical imaging expertise to help them quickly identify the most promising imaging solutions to accelerate the drug development process," said Todd Joron, Corporate Vice President and General Manager at Perceptive Informatics.
Perceptive Informatics' medical imaging scientific advisors include:

-- Suhny Abbara, M.D., Assistant Professor, Harvard Medical School, and

Director, Cardiovascular Imaging Section, Massachusetts General

Hospital

-- Matthew A Barish, M.D., Assistant Clinical Professor and Director of

MRI at Stony Brook University Medical Center, Co-Director, Tumor

Imaging Metrics Core, Dana Farber/Harvard Cancer Center for Brigham and

Women's Hospital, Assistant Professor of Radiology, Harvard Medical

School

-- Frederik Barkhof, M.D., Ph.D., Professor of Neuroradiology and Director

of the Image Analysis Centre, Vrije Universiteit Medical Centre, Co-

Chairman MAGNIMS study group on multiple sclerosis, and Imaging PI,

European Alzheimer Disease Neuroimaging Initiative

-- Henri Francois Cuenoud, M.D., Associate Professor in Medicine, in the

areas of cardiovascular medicine and non-invasive cardiology, and Non-

Invasive Cardiologist, UmassMemorial and University of Massachusetts

Medical School.

-- Mark Stephen Huberman, M.D., Diplomat, Medical Oncology, American Board

of Internal Medicine, Beth Israel Deaconess Hospital and Assistant

Professor of Medicine, Harvard University Medical School

-- Gregory S. Karczmar, Ph.D., Director of MRIS Research Facility,

Department of Radiology, University of Chicago, and Dynamic Contrast-

Enhanced Magnetic Resonance Imaging (DCE-MRI) expert

-- William E. Palmer, M.D., Director, Musculoskeletal Imaging,

Massachusetts General Hospital and Assistant Professor of Radiology,

Harvard Medical School

-- Max P. Rosen, M.D. MPH, Associate Chief of Radiology for Community

Network Services, Beth Israel Deaconess Medical Center, Associate

Professor of Radiology, Harvard Medical School, Interventional

Radiologist and Abdominal Imaging Sub-specialist, Beth Israel Deaconess

Medical Center

-- Yair I. Safriel, M.D., Neuroradiologist and Assistant Clinical

Professor, Neuroradiology Section, Yale University School of Medicine

and Dunedin NeuroSpine Institute

-- Barry A. Siegel, M.D., Professor of Radiology and Medicine at

Washington University School of Medicine, Director of the Division of

Nuclear Medicine at Mallinckrodt Institute of Radiology, and expert in

the area of positron emission tomography (PET) in oncology

-- Neil J. Weissman, M.D., FACC, President of Medstar Research Institute,

Professor of Medicine, Georgetown University School of Medicine, and

Director of Ultrasound Core Laboratories at the Cardiovascular Research

Institute at Washington Hospital Center

-- Cheng Yang, Ph.D., Research Associate at the Department of Medicine,

the University of Chicago, and DCE-MRI expert

Perceptive Informatics' Medical Imaging division leverages advanced technology to ensure the effective use of imaging surrogate endpoint data as well as secure data access and back-up. The Perceptive Informatics medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology.

About Perceptive Informatics, a PAREXEL Company

PAREXEL's Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive's portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(R) solution is Perceptive's market-leading CTMS product with 26,000 users worldwide, and Perceptive's INITIATOR(TM) trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit http://www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has approximately 7,000 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2007 as filed with the SEC on November 7, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird, Director of Public Relations Rebecca Passo

PAREXEL International SHIFT Communications

Tel: +781-434-4409 Tel: +617-779-1817

Email: Jennifer.Baird@PAREXEL.com Email: rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. InfoLogix Acquires Healthcare Informatics Associates Inc. (HIA); Adds Premier Healthcare Consulting Firm and Systems Integrator
2. AMIA Announces Partnership with CDC to Enhance Public Health Informatics
3. BioDiscovery Joins Illumina Connect Bioinformatics Program
4. General Motors, Virginia Tech scientists collaborate to advance neuroinformatics
5. WorldHeart Appoints David Pellone Chief Financial Officer
6. Novo Nordisk Appoints New Leader of North American Business
7. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
8. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
9. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
10. Resonant Medical Appoints New Vice President of Global Sales
11. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency ... to assist the local community. Pledging to select a new beneficiary every 60 ... the area. Their goal is to bring community awareness to important local causes ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... three leading bottled water brand owners that topped the list as a result of ... optimize conversion. The premier brand was Tibet 5100, a top notch water company that ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Dr. Jessica ... the practice is now accepting new dental patients and families in the North Metro ... dental care services from cleanings to cosmetic dentistry, and all in the most relaxing ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, LLC, ... new approaches to the treatment of lupus and ... a multiple ascending dose study in patients with ... RSLV-132. --> --> ... multiple ascending dose study of RSLV-132 in 32 ...
(Date:2/10/2016)... Urologix, the market leader for in-office minimally ... Hyperplasia (BPH), announces new private ownership and is operating ... device industry veteran of more than 20 years, has ... Plymouth, Minn. The company,s ... Prostiva® RF Therapy, will continue to be broadly available ...
(Date:2/10/2016)... -- Astellas Pharma Inc. (TSE: 4503, President and CEO: ... successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition ... and outstanding shares of common stock of Ocata Therapeutics, ... , "Ocata") for a price of US$8.50 per share ... commenced the Tender Offer on November 19, 2015, U.S. ...
Breaking Medicine Technology: